Kazia Therapeutics(US:KZIA) Benzinga·2025-11-19 08:52Core Insights - Kazia Therapeutics Limited (NASDAQ: KZIA) shares surged 51.74% in after-hours trading to $8.74 following the release of promising clinical data on metastatic triple-negative breast cancer (TNBC) [1][2] Clinical Data - A patient with stage IV TNBC achieved an immune-complete response under an FDA-approved single-patient expanded access protocol, combining paxalisib with pembrolizumab (Keytruda) and standard chemotherapy [2] - After three months of treatment, a PET/CT scan indicated that all previously identified lesions had completely resolved metabolically, with the patient's tumor burden reduced by 86% after just three weeks of treatment [3] Rare Clinical Outcome - Complete responses in stage IV metastatic TNBC are extremely rare, and the initial complete response observed is considered an encouraging clinical finding by the CEO of Kazia Therapeutics [4] Upcoming Scientific Presentations - Kazia announced acceptance of two presentations at the 2025 San Antonio Breast Cancer Symposium, focusing on a Phase 1b study of paxalisib combined with olaparib or pembrolizumab/chemotherapy, and liquid biopsy tracking of PI3K-mTOR residual disease signatures in metastatic breast cancer [5] Nasdaq Compliance Concerns - Kazia Therapeutics received a staff determination letter from Nasdaq indicating it did not meet the $35 million minimum Market Value of Listed Securities requirement by the Nov. 10 deadline, and plans to request a hearing to address this issue [6] Stock Performance - Year-to-date, Kazia Therapeutics has fallen 34.02%, but has risen 58.24% over the past six months, with a market capitalization of $9.56 million and shares trading between $2.86 and $30.05 over the past year [7] - The stock closed at $5.76, down 5.29% in the regular session, but has a positive price trend across all time frames according to Benzinga Edge Stock Rankings [8]